 | • レポートコード：MRC2303I0063 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の副腎皮質ステロイド市場規模が、予測期間中（2022年〜2027年）に年平均4.3%で成長すると予測しています。本レポートは、副腎皮質ステロイドの世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（グルココルチコイド、ミネラルコルチコイド）分析、投与経路別（局所ステロイド、吸入ステロイド、経口剤、全身投与用製剤、その他）分析、用途別（リウマチ適応症、皮膚アレルギー、内分泌学、消化器科、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、Pfizer Inc.、Novartis AG、Sanofi S.A.、GlaxoSmithKline plc、Cipla Inc.、Johnson & Johnson Services, Inc.、AstraZeneca plc、Merck & Co., Inc.,、Sumitomo Corporation、Leo Pharma、Bayer Pharmaceuticalなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の副腎皮質ステロイド市場規模：製品別 - グルココルチコイドの市場規模 - ミネラルコルチコイドの市場規模 ・世界の副腎皮質ステロイド市場規模：投与経路別 - 局所ステロイドの市場規模 - 吸入ステロイドの市場規模 - 経口剤の市場規模 - 全身投与用製剤の市場規模 - その他投与経路の市場規模 ・世界の副腎皮質ステロイド市場規模：用途別 - リウマチ適応症における市場規模 - 皮膚アレルギーにおける市場規模 - 内分泌学における市場規模 - 消化器科における市場規模 - その他用途における市場規模 ・世界の副腎皮質ステロイド市場規模：地域別 - 北米の副腎皮質ステロイド市場規模 アメリカの副腎皮質ステロイド市場規模 カナダの副腎皮質ステロイド市場規模 メキシコの副腎皮質ステロイド市場規模 … - ヨーロッパの副腎皮質ステロイド市場規模 ドイツの副腎皮質ステロイド市場規模 イギリスの副腎皮質ステロイド市場規模 フランスの副腎皮質ステロイド市場規模 … - アジア太平洋の副腎皮質ステロイド市場規模 中国の副腎皮質ステロイド市場規模 日本の副腎皮質ステロイド市場規模 インドの副腎皮質ステロイド市場規模 … - 中東/南米の副腎皮質ステロイド市場規模 南アフリカの副腎皮質ステロイド市場規模 ブラジルの副腎皮質ステロイド市場規模 アルゼンチンの副腎皮質ステロイド市場規模 … - その他地域の副腎皮質ステロイド市場規模 ・競争状況 ・市場機会・将来の動向 |
The corticosteroid market is expected to witness a CAGR of 4.3% during the forecast period (2022-2027).
The COVID-19 pandemic has had a substantial influence on worldwide healthcare systems, as well as the market for corticosteroids. Early in the pandemic, epidemiological data showed that people with Chronic obstructive pulmonary disease (COPD) and asthma had a decreased rate of COVID-19 infection, leading to the suggestion that inhaled corticosteroids would help. In addition, in September 2020, the World Health Organization collaborated with investigators from seven corticosteroid trials to conduct a prospective meta-analysis of randomized trials for corticosteroid therapy for COVID-19 (PMA) to quickly provide additional evidence to complement the RECOVERY data and inform guidance development, according to a World Health Organization report due in September 2020. Moreover, according to the article published in BMC Infectious Disease in May 2021, in hospitalized hypoxic COVID-19 patients, methylprednisolone demonstrated better results compared to dexamethasone. As a result, the increased usage of corticosteroids in the treatment of COVID-19 patients demonstrates COVID-19’s significant impact on the market.
The major factors accounting for the growth of the corticosteroid market are increasing the incidence of chronic diseases, the growing geriatric population, and surging investment in research and development. According to the United Nations report 2020, the estimated human population is expected to increase from 7.2 billion today to 8.2 billion by 2025. This, in turn, raises the global burden of chronic diseases to 57 percent by the end of 2020. According to the Centers for Disease Control and Prevention 2020 report, in the United States, approximately 25 million Americans have asthma. This equals to about 1 in 13 Americans, including 8% of adults and 7% of children. About 20 million United States adults aged 18 years and over have asthma. Corticosteroids are majorly used in the treatment of asthma, and the rising prevalence of it boosts the market growth over the forecast period.
Furthermore, according to the World Ageing 2020 report, in 2020, there were around 727 million people aged 65 years or more in the world. The number of older persons is projected to double to 1.5 billion in 2050. the geriatric population is more prone to chronic diseases which require corticosteroid therapy for various diseases that will help grow the market in the years to come.
Hence, this uninterrupted incidence and prevalence of chronic diseases lead to the growth of the Corticosteroids market during the forecast period. However, the risk factors associated with the prolonged use of corticosteroids hampers the growth of the market to some extent.
Corticosteroids Market Trends
Topical Steroids segment by Route of Administration Dominates the Market During the Forecast Period
Topical corticosteroids are a type of steroid medicine applied directly to the skin to reduce inflammation and irritation. Topical corticosteroids are available in several different forms, including creams, lotions, and gels.
Topical steroids are used in treating the skin conditions such as rash, dermatitis, itching, eczema, and psoriasis, and this segment is expected to dominate the market due to the continuous growth of the geriatric population with rising skin diseases around the world and the extended storage capacity of the topical corticosteroids.
As aging results in the decline of the normal functioning of organ systems, including skin, the geriatric population is highly prone to skin diseases. According to the data from World Population Prospects 2022, the share of the global population aged 65 years or above is projected to rise from 10 per cent in 2022 to 16 per cent in 2050. By 2050, the number of persons aged 65 years or over worldwide is projected to be more than twice the number of children under age 5 and about the same as the number of children under age 12. In terms of convenience, the geriatric population with skin diseases prefers to use topical steroids.
All these factors together support that Topical steroids dominate the corticosteroids market.
North America Dominates the Market and the Same is Expected Over the Forecast Period.
North America is expected to dominate the overall market throughout the forecast period, which is attributed to the developed economy, increasing health care expenditure, increasing incidence of lifestyle-related diseases, and high adoption of technologically advanced products in the region.
According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases were diagnosed in the United States in 2020. In 2020, The most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in the United States. Furthermore, According to the Centers for Disease Control and Prevention 2020 report, in the United States, approximately 25 million Americans have asthma. This equals to about 1 in 13 Americans, including 8% of adults and 7% of children. About 20 million United States adults aged 18 years and over have asthma. Also, according to the Asthma and Allergy Foundation of America (AAFA), in 2021, roughly 1 in 13 Americans had asthma, which is about 25 million people. As per the same source, about 5 million American children have asthma which strongly supports North America to dominate the market during the forecast period.
Furthermore, in the United States, asthma is more common in adult women than in adult men. According to the Centers for Disease Control and Prevention 2020 report, in the United States, approximately 25 million Americans have asthma. This equals to about 1 in 13 Americans, including 8% of adults and 7% of children. About 20 million United States adults age 18 and over have asthma. Similarly, asthma is a major public health concern in Canada. As a lifelong respiratory illness, asthma affects the work productivity, quality of life, mental health, and psychological well-being of the Canadian population.
Thus, the increasing prevalence of asthma is expected to raise the demand for corticosteroids, thereby boosting the market in the region.
Corticosteroids Market Competitor Analysis
The corticosteroid market is moderately competitive and consists of several major players. With the increasing consolidations of various organizations in the healthcare sector, it is expected to generate competitive rivalry among the key players in the future. Some of the major players in the market are Pfizer Inc., Novartis, AstraZeneca, GSK, Cipla Inc., Merck, etc.,
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Geriatric Population and Increasing Incidence of Chronic Diseases
4.2.2 Surging investment in Research and Development
4.3 Market Restraints
4.3.1 Pricing Pressure on the Companies by the Government
4.3.2 Risk factors associated with Corticosteriods on Prolonged use
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Product
5.1.1 Glucocorticoids
5.1.2 Mineralocorticoids
5.2 By Route of administration
5.2.1 Topical steroids
5.2.2 Inhaled steroids
5.2.3 Oral forms
5.2.4 Systemic forms
5.2.5 Others
5.3 By Application
5.3.1 Rheumatology indications
5.3.2 Skin allergies
5.3.3 Endocrinology
5.3.4 Gastroenterology
5.3.5 Acute respiratory diseases
5.3.6 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Novartis AG
6.1.3 Sanofi S.A.
6.1.4 GlaxoSmithKline plc
6.1.5 Cipla Inc.
6.1.6 Johnson & Johnson Services, Inc.
6.1.7 AstraZeneca plc
6.1.8 Merck & Co., Inc.,
6.1.9 Sumitomo Corporation
6.1.10 Leo Pharma
6.1.11 Bayer Pharmaceutical
7 MARKET OPPORTUNITIES AND FUTURE TRENDS